Your browser doesn't support javascript.
loading
Tolerability, Safety, Pharmacokinetics, and Immunogenicity of a Novel SARS-CoV-2 Neutralizing Antibody, Etesevimab, in Chinese Healthy Adults: a Randomized, Double-Blind, Placebo-Controlled, First-in-Human Phase 1 Study.
Wu, Xiaojie; Li, Nanyang; Wang, Guoqin; Liu, Wei; Yu, Jicheng; Cao, Guoying; Wang, Jingjing; Chen, Yuancheng; Ma, Juan; Wu, Jufang; Yang, Haijing; Mao, Xiaomeng; He, Jinjie; Yu, Yiqi; Qiu, Chao; Li, Ning; Yao, Sheng; Feng, Hui; Yan, Jinghua; Zhang, Wenhong; Zhang, Jing.
Afiliação
  • Wu X; Phase 1 Clinical Research Center, Huashan Hospital, Fudan University, Shanghai, China.
  • Li N; Phase 1 Clinical Research Center, Huashan Hospital, Fudan University, Shanghai, China.
  • Wang G; Medical Science, Shanghai Junshi Biosciences Co., Ltd., Beijing, China.
  • Liu W; Medical Science, Shanghai Junshi Biosciences Co., Ltd., Beijing, China.
  • Yu J; Phase 1 Clinical Research Center, Huashan Hospital, Fudan University, Shanghai, China.
  • Cao G; Phase 1 Clinical Research Center, Huashan Hospital, Fudan University, Shanghai, China.
  • Wang J; Phase 1 Clinical Research Center, Huashan Hospital, Fudan University, Shanghai, China.
  • Chen Y; Phase 1 Clinical Research Center, Huashan Hospital, Fudan University, Shanghai, China.
  • Ma J; Medical Science, Shanghai Junshi Biosciences Co., Ltd., Beijing, China.
  • Wu J; Phase 1 Clinical Research Center, Huashan Hospital, Fudan University, Shanghai, China.
  • Yang H; Phase 1 Clinical Research Center, Huashan Hospital, Fudan University, Shanghai, China.
  • Mao X; Phase 1 Clinical Research Center, Huashan Hospital, Fudan University, Shanghai, China.
  • He J; Phase 1 Clinical Research Center, Huashan Hospital, Fudan University, Shanghai, China.
  • Yu Y; Department of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, China.
  • Qiu C; Department of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, China.
  • Li N; Medical Science, Shanghai Junshi Biosciences Co., Ltd., Beijing, China.
  • Yao S; Medical Science, Shanghai Junshi Biosciences Co., Ltd., Beijing, China.
  • Feng H; Medical Science, Shanghai Junshi Biosciences Co., Ltd., Beijing, China.
  • Yan J; CAS Key Laboratory of Microbial Physiological and Metabolic Engineering, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.
  • Zhang W; Department of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, China.
  • Zhang J; Phase 1 Clinical Research Center, Huashan Hospital, Fudan University, Shanghai, China.
Antimicrob Agents Chemother ; 65(8): e0035021, 2021 07 16.
Article em En | MEDLINE | ID: mdl-33972256
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: SARS-CoV-2 / COVID-19 Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Adult / Humans País/Região como assunto: Asia Idioma: En Revista: Antimicrob Agents Chemother Ano de publicação: 2021 Tipo de documento: Article País de afiliação: China
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: SARS-CoV-2 / COVID-19 Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Adult / Humans País/Região como assunto: Asia Idioma: En Revista: Antimicrob Agents Chemother Ano de publicação: 2021 Tipo de documento: Article País de afiliação: China